The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .
Racial differences in response to low-dose captopril are abolished by the addition of hydrochlorothiazide.
1 In a r and omised study , 475 men with diastolic blood pressures of 92 - 109 mm Hg received either placebo or captopril 37.5 mg , 75 mg or 150 mg/day for 7 weeks . 2 After 7 weeks patients taking placebo were given hydrochlorothiazide 25 mg twice daily , as were two-thirds of each group taking captopril and they were observed for 7 additional weeks . 3 Captopril reduced blood pressure by 12.2 + /- 0.8/9.4 + /- 0.4 mm Hg at 7 weeks ( n = 323 ) and captopril plus placebo reduced it by 10.3 + /- 1.9/10.2 + /- 0.9 mm Hg at 14 weeks ( n = 83 ) ; placebo by 2.0 + /- 1.7/3.4 + /- 0.8 mm Hg ( n = 76 ) ; and captopril plus hydrochlorothiazide by 24.4 + /- 1.1/16.2 + /- 0.6 mm Hg ( n = 173 ) . The effect of low-dose captopril was similar to that of high doses . 4 White patients responded better than blacks , with a blood pressure reduction of 14.7 + /- 1.1/10.7 + /- 0.6 mm Hg ( n = 170 ) v 9.1 + /- 1.2/8.0 + /- 0.7 mm Hg ( n = 151 ) . This difference was abolished by the addition of hydrochlorothiazide . 5 Only 15/384 ( 3.9 % ) of patients were dropped from the study because of adverse effects . 6 The prescription of low-dose captopril might be extendable to patients with mild to moderate hypertension
The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .